Subscribe To
ALLK / Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
ALLK News
By The Motley Fool
September 27, 2023
Why Shares of Allakos Are Up Wednesday
An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders. more_horizontal
By Seeking Alpha
September 18, 2023
Scratching The Surface: Allakos' Novel Take On Urticaria
Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirenteli more_horizontal
By Seeking Alpha
May 21, 2023
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74 more_horizontal
By The Motley Fool
May 12, 2023
Why Allakos Stock Skyrocketed Nearly 9% Higher Today
An analyst bumped his recommendation higher. This closely followed an encouraging quarterly earnings report/business update from the biotech. more_horizontal
By The Motley Fool
March 7, 2023
Why Allakos Stock Was Heating Up Today
Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An analyst thinks these twin catalysts could cause the more_horizontal
By Zacks Investment Research
December 9, 2022
Allakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal
By The Motley Fool
March 7, 2022
Why Allakos Stock Sank 17.3% in February
The biotech stock has lost roughly 96% of its value over the last year. more_horizontal
By The Motley Fool
March 7, 2022
Why Allakos Stock Sank 17.3% in February
The biotech stock has lost roughly 96% of its value over the last year. more_horizontal